EFFICACY OF RUFINAMIDE IN THE TREATMENT OF DRUG-RESISTANT FOCAL EPILEPSIES IN PAEDIATRIC PRACTICE

I. O. Shchederkina; Щедеркина И. О.; K. A. Orlova; Орлова К. А.; I. E. Koltunov; Колтунов И. Е.; M. Yu. Dorofeeva; Дорофеева М. Ю.

doi:10.17650/2073-8803-2016-11-4-54-60

EFFICACY OF RUFINAMIDE IN THE TREATMENT OF DRUG-RESISTANT FOCAL EPILEPSIES IN PAEDIATRIC PRACTICE

Authors: Shchederkina I.O.¹^,2, Orlova K.A.¹^,2, Koltunov I.E.¹^,3, Dorofeeva M.Y.⁴
Affiliations:
1. Morozov Children’s City Clinical Hospital, Moscow Healthcare Department
2. N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
3. Peoples’ Friendship University of Russia
4. Acad. Yu.E. Vel’tishchev Research Clinical Institute of Pediatrics, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Issue: Vol 11, No 4 (2016)
Pages: 54-60
Section: CLINICAL OBSERVATIONS
Published: 28.02.2017
URL: https://rjdn.abvpress.ru/jour/article/view/185
DOI: https://doi.org/10.17650/2073-8803-2016-11-4-54-60
ID: 185

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Among drug-resistant epilepsies, epileptic syndromes, characterized by combination of several types of seizures, are considered to be the most difficult in terms of treatment. Lennox–Gastaut syndrome is one of them. It manifests with polymorphic seizures (tonic axial, myatonic, atypical absence seizures, status epilepticus of minor motor seizures, myoclonic, generalized convulsive, and focal seizures). This is a heterogeneous disease, represented by a complex of clinical and electroencephalographic manifestations with various etiology. Current review is devoted to a novel antiepileptic drug rufinamide, which has a new mechanism of action. The drug has been registered in Russia in 2015. The authors also describe their own experience of rufinamide usage in the treatment of drug-resistant focal epilepsy as a part of multicomponent therapy for polymorphic seizures. One patient achieved clinical remission for 16 months; the second one had more than 50 % decrease in seizures frequency with a remission of drop-attacks.

Keywords

drug-resistant epilepsy, polymorphic seizures, Lennox–Gastaut syndrome, rufinamide, Inovelon

About the authors

I. O. Shchederkina

Morozov Children’s City Clinical Hospital, Moscow Healthcare Department;
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

Author for correspondence.
Email: schederkina@bk.ru

1/9 4th Dobryninskiy Pereulok, Moscow 119049;

1 Ostrovityanova St., Moscow, 117997

Russian Federation

K. A. Orlova

Morozov Children’s City Clinical Hospital, Moscow Healthcare Department;
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

Email: fake@neicon.ru

1/9 4th Dobryninskiy Pereulok, Moscow 119049;

1 Ostrovityanova St., Moscow, 117997

Russian Federation

I. E. Koltunov

Morozov Children’s City Clinical Hospital, Moscow Healthcare Department;
Peoples’ Friendship University of Russia

Email: fake@neicon.ru

1/9 4th Dobryninskiy Pereulok, Moscow 119049;

6 Miklukho-Maklaya St., Moscow 117198

Russian Federation

M. Yu. Dorofeeva

Acad. Yu.E. Vel’tishchev Research Clinical Institute of Pediatrics, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

Email: fake@neicon.ru
2 Taldomskaya St., Moscow 125412 Russian Federation

References

Supplementary files

Supplementary Files

Action

1. JATS XML

Download

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register